Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Sales of Investments
Cash received from selling or redeeming investments.
Apogee Therapeutics, Inc.NASDAQ: APGE
Sales of Investments · Q2 FY2026 · quarter ended Jun 2026
Sales of investments growth accelerates
Q2 FY2026 sales of investments of $170.88M rose 35.3% year over year, ahead of the +24.1% change in trailing-twelve-month sales of investments. Sequentially, it rose 15.5% from the prior quarter.
Context
- Sales of investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +35.3% holds above the trailing-twelve-month pace of +24.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 467.87M USD
- Year-over-year change
- +33.6%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 467.87M | +33.6% |
| FY2024 | 2024-12-31 | 350.14M | +1067.1% |
| FY2023 | 2023-12-31 | 30M | — |
| FY2022 | 2022-12-31 | 0 | — |
Sales of Investments vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.1% is the 4th highest of 9, against a peer median of -1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.02B USD | -79.1% | +105.5% | 75.2% | |
| LTM Sep 2026 | $871.69M USD | +2.5% | — | 14137.0% | |
| LTM Sep 2026 | $818.03M USD | +32.8% | +30.6% | — | |
| LTM Mar 2026 | $709.09M USD | +238.3% | — | — | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $545.64M USD | +39.0% | — | — |
| LTM Jun 2026 | $544.88M USD | +24.1% | — | — | |
| LTM Mar 2026 | $395.01M USD | -5.6% | -6.6% | 59.0% | |
| LTM Jun 2026 | $300.77M USD | -48.0% | — | — | |
| LTM Jun 2026 | $0 USD | -100.0% | -22.3% | 0.0% | |
AAPGAscentage Pharma Group International | FY2025 | CN¥0 CNY | — | — | 0.0% |
| Peer median (excluding APGE) | — | -1.6% | +12.0% | 59.0% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (39.79M) | (83.99M) | (182.15M) | (255.84M) |
| Depreciation & Amortization | 0 | 0 | 189K | 1.42M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.14M | 6.1M | 23.33M | 46.28M |
| Change in Working Capital | 9.82M | 6.11M | (2M) | (15.48M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 418K | 1.61M | (1.07M) | 150K |
| Other Working Capital | 9.4M | 4.49M | (930K) | (15.63M) |
| Other Non-Cash Items | 11.4M | (2.98M) | (10.55M) | (3.82M) |
| Operating Cash Flow | (16.43M) | (74.76M) | (171.17M) | (227.45M) |
| Capital Expenditures | 0 | (167K) | (1.15M) | (5.15M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (303.74M) | (649.45M) | (642.3M) |
| Sales of Investments | 0 | 30M | 350.14M | 467.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (273.91M) | (300.46M) | (179.57M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 168.32M | 315.39M | 493.48M | 396.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 1.63M | 0 |
| Financing Cash Flow | 168.32M | 315.39M | 495.11M | 396.49M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 151.89M | (33.28M) | 23.47M | (10.53M) |
| Free Cash Flow | (16.43M) | (74.93M) | (172.33M) | (232.6M) |
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.